Roivant Sciences (ROIV)

• Market cap: $9.53B
• 1 day: -0.92%
• 5 days: 8.14%
• 1 month: 17.72%
• 3 months: 25.9%
• 6 months: 28.57%
• Year to date: 15.48%
• 1 year: 15.86%
• 5 years: 49.2%
• 10 years: 49.2%
• Sector: Healthcare
• Industry: Biotechnology

About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Employees: 750

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

690% more call options, than puts

Call options by funds: $87.5M | Put options by funds: $11.1M

80% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 35

8% more funds holding

Funds holding: 310 [Q1] → 335 (+25) [Q2]

5% more repeat investments, than reductions

Existing positions increased: 114 | Existing positions reduced: 109

4% more capital invested

Capital invested by funds: $5.58B [Q1] → $5.8B (+$215M) [Q2]

1.86% less ownership

Funds ownership: 77.55% [Q1] → 75.69% (-1.86%) [Q2]

28% less funds holding in top 10

Funds holding in top 10: 18 [Q1] → 13 (-5) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16
• Avg. target: $17
• High target: $18

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Samantha Semenkow	$16	Buy Initiated	2 Sep 2025
HC Wainwright & Co. Douglas Tsao	$18	Buy Reiterated	18 Jun 2025